In a particular investigation, the FDA examined the application of proteomics, which involves the comprehensive analysis of proteomes or sets of proteins, to uncover biomarkers for Parkinson’s disease (PD) in biological treatments such as IFNβ-1a and pegylated-IFNβ-1a (pegIFNβ-1a). Here, GDI1 is linked to Parkinson disease.